Le Lézard
Classified in: Health
Subjects: TRI, FDA

CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

SHANGHAI, Aug. 30, 2019 /PRNewswire/ -- CARsgen Therapeutics Inc., a clinical-stage biopharmaceutical company today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to its investigational CAR-T cell therapy fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cells (ct053) for the treatment of multiple myeloma.

"FDA orphan designation is an important regulatory milestone in the continued development and commercialization of CT053 anti-BCMA CAR-T cells," said Dr. Zonghai Li, Founder, CEO and CSO of CARsgen. "CT053 has demonstrated outstanding potency in an exploratory phase 1 clinical study in China. A total of 19 of 24 patients with relapsed and refractory multiple myeloma showed complete response. And importantly, no event of grade 3 or higher cytokine release syndrome (CRS) was observed." The CT053 anti-BCMA CAR-T program has received Investigational New Drug (IND) clearance from the US FDA.

Orphan drug designation is granted by the FDA Office of Orphan Products Development to pharmaceutical products which are intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. Under the Orphan Drug Act, the CT053 anti-BCMA product would be eligible for certain benefits including seven years of market exclusivity in the United States following marketing approval by the FDA.

About CARsgen Therapeutics, Inc.
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development and commercialization of CAR-T therapeutics for unmet medical need. The company has collaborated with top hospitals in China to launch several other First-in-Human studies such as anti-GPC3 CAR-T for hepatocellular carcinoma and squamous lung cancer, anti-EGFR/EGFRvIII CAR-T for glioblastoma multiforme and anti-Claudin18.2 CAR-T for gastric and pancreatic cancer.

For more information, please visit: www.carsgen.com

Related Links


SOURCE CARsgen Therapeutics Co. Ltd.

These press releases may also interest you

5 jui 2020
HitGen Inc. (HitGen, 688222.SH) announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen's industry-leading DNA-encoded...

5 jui 2020
Everbright is pleased to confirm another large shipment of PPE arrived in Vancouver in June. Orders can be placed online for Authorized Medical Use KN95 Masks, ASTM Level 2 Surgical Masks, Disposable Face Masks, ANSI/AAMI Level 3 Surgical Gowns,...

5 jui 2020
The American Medical Veterinary Association (AVMA) interviewed Seth Wallack, DVM, Board Certified Veterinary Radiologist and Founder of Vetology® and Eric Goldman, President of Vetology® AI. Dr. Wallack and Eric Goldman discussed upcoming challenges...

5 jui 2020
Two doctors from Congressional OB GYN and a dentist in Maryland are the organizers of the "COVID-19 Challenge" with the hopes of attracting public interest and coordinating a national effort to reverse the recent trends in the coronavirus pandemic by...

5 jui 2020
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 105,317 cases of COVID-19 in Canada, including 8,674 deaths. 66% of people have now recovered....

5 jui 2020
The latest data of the evolution of COVID-19 in Québec reveal 79 new cases over the past 24 hours, bringing the total number of people infected to 55,863. During the same period, 1 new death was recorded, to which are added 7 deaths that occurred...

News published on 30 august 2019 at 22:54 and distributed by: